[1] 王英杰. 肝衰竭:定义、诊断与治疗.中华肝脏病杂志,2008,16:725-727.
[2] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012版). 中华临床感染病杂志,2012,5:321-327.
[3] 刘志国,毛远丽.凝血检查在肝病中的临床应用进展.中华检验医学杂志,2008,31:710-712.
[4] Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology, 2010, 52: 249-255.
[5] LaBonte ML. Anticoagulant factor V: factors affecting the integration of novel scientific discoveries into the broader framework. Stud Hist Philos Biol Biomed Sci, 2014, 47: 23-34.
[6] Cramer TJ, Griffin JH, Gale AJ. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb, 2010, 37: 17-23.
[7] 张冬磊,郝建宇,杨宁. 肝硬化纤溶和抗凝指标变化及其与血清白蛋白相关性分析. 中国医师进修杂志,2014,37:4-7.
[8] 陈静,丛玉隆. 止凝血相关指标在慢性乙型肝炎与肝硬化及肝衰竭中的变化趋势.中华检验医学杂志,2015,38:128-130.
[9] 李良瑛,王娜,袁萍萍. 慢加急性肝衰竭患者凝血功能检测及临床意义.实用肝脏病杂志,2011,14:363-364.
[10] Deicher SR. Interpretation of the internatianal normalised ratio in patients with liver disease. Lancet, 2002, 359: 47-48.
[11] 曾淑燕,张端伟,余展超. 口服华法林患者凝血因子Ⅶ活性的变化.血栓与止血学,2005,11:213-214.
[12] 肝性脑病诊断治疗专家委员会.肝性脑病诊断治疗专家共识.中华实验和临床感染病杂志(电子版),2009,3:449-473. |
